 |
Founded in 1942 by Dr. Nejat F. Eczacıbaşı, the Eczacıbaşı Group takes
its name from the honorary title “chief pharmacist”, conferred on the
father of Dr. Eczacıbaşı at the turn of the last century. Eczacıbaşı is a
prominent Turkish industrial group with 39 companies, 9,300 employees and
a combined net turnover of TL 3.8 billion in 2009.
Eczacıbaşı’s core sectors are building products,healthcare and consumer products.
Additionally, the Group is active in finance, information technology, welding
technology and real estate. In Turkey, Eczacıbaşı is the leader in most of
its businesses and has distribution networks for pharmaceuticals, building
products and fast-moving consumer goods that are among the strongest in their
sectors. Internationally, Eczacıbaşı is best known for its flagship VitrA
brand, a powerful contender in global bathroom and tile markets. It is also a
major exporter of tissue paper, pharmaceuticals, welding electrodes, electronic
smart cards and industrial raw materials such as clay and feldspar.
International partnership is a central component of the Eczacıbaşı Group’s
growth strategy. Eczacıbaşı has nine international joint ventures and numerous
cooperation agreements with leading international companies. All of these
are grounded on the principle of long-term mutual benefit, based on firm
business criteria and ethical business practices.
The Eczacıbaşı Group’s mission is to be a pioneer of modern, high quality
and healthy lifestyles. Accordingly, the Group encourages each of its companies
to surpass established standards in their sectors and raise consumer benchmarks
of product and service quality. Through sponsorship and responsible corporate
practices, it also promotes social and economic development that nurtures cultural
and scientific activity, protects the environment and preserves scarce natural resources.
www.eczacibasi.com.tr
. 64 manufacturing facilities in 27 countries
. Activities in more than 110 countries
. 46,5 thousand employees
. 2007 sales: 11,3 billion USD
. R&D expenditures (2004): 760 million USD
. 25% of the world parenteral solutions market
. 50% of the American parenteral solutions market
Baxter has provided a number of products and services in the field of medicine
ranging from the first commercially manufactured intravenous (IV) solutions to
the first commercially manufactured artificial kidney, valve,
HomeChoice dialysis device that cleans the blood of the patient
through the night, automatic blood cell separation system and treatment of
hemophilia patients with genetic engineering methods for the first time.
50% of the sales income of Baxter is gained from outside USA and its products
are being sold in more than 110 countries.
Baxter is operating in five different geographical regions Asia Pasific,
Canada, Europe, Latin America and United States. And Turkey is
included among ECEMEA/Europe group.
Most of the products are manufactured by state of the art technology and
manufacturing in all the facilities of Baxter is continued with the highest
quality standards.
Baxter has more than 46,500 talented employees all over the
world who commit themselves to their jobs and who work with the aim of
increasing the life quality of as many people as possible.
www.baxter.com
|
|